Han All Biopharma
Biotechnology, 1 Church St, Seoul, Maryland, 20850, United States, 201-500 Employees
Phone Number: +13*********
Who is HANALL BIOPHARMA
HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patient...
Read More
-
Headquarters: 1 Church St, Seoul, Maryland, 20850, United States
-
Date Founded: 1973
-
Employees: 201-500
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from HANALL BIOPHARMA
HanAll Biopharma Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding HanAll Biopharma
Answer: HanAll Biopharma's headquarters are located at 1 Church St, Seoul, Maryland, 20850, United States
Answer: HanAll Biopharma's phone number is +13*********
Answer: HanAll Biopharma's official website is https://hanall.co.kr
Answer: HanAll Biopharma's revenue is $1 Million to $5 Million
Answer: HanAll Biopharma's SIC: 2834
Answer: HanAll Biopharma's NAICS: 325412
Answer: HanAll Biopharma has 201-500 employees
Answer: HanAll Biopharma is in Biotechnology
Answer: HanAll Biopharma contact info: Phone number: +13********* Website: https://hanall.co.kr
Answer: HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for 50 years. HanAll has also expanded its focus to ophthalmology, immunology, oncology, and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials worldwide for the treatment of autoimmune diseases, including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves disease (GD). Another key asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month